Generic placeholder image

Current Cardiology Reviews

Author(s): Milad Modarresi, Ahmed Amro*, Mohammad Amro, Amal Sobeih, Uzo Okoro, Kanaan Mansoor, Carlos Rueda, Rawan Elhamdani, Nesreen BenHamed, Timothy Kocher and Mehiar Elhamdani

DOI: 10.2174/1573403X16666200313103657

DownloadDownload PDF Flyer Cite As
Management of Cardiogenic Shock due to Thyrotoxicosis: A Systematic Literature Review

Page: [326 - 332] Pages: 7

  • * (Excluding Mailing and Handling)

Abstract

Background: A grave complication of thyrotoxicosis, or thyroid storm, is the development of heart failure and cardiomyopathy. Recognizing this condition is imperative in preventing further left ventricular dysfunction and cardiogenic shock. This manuscript aims to review the literature on cardiogenic shock associated with thyrotoxicosis and present management recommendations on this rare condition.

Methods: A literature search was performed in December of 2018, using the PubMed medical search engine. A systematic search was carried out using the keywords Thyroid Storm AND Cardiogenic Shock and Thyrotoxicosis AND Shock.

Management: Decrease of thyroid hormone levels using therapeutic plasma exchange LV Unloading and ventilation by Impella and Extracorporeal Mechanical Ventilation (ECMO).

Conclusion: Patients presenting with thyroid storm-induced shock may not be suitable candidates for traditional management with β -adrenergic blockers (β-blockers). The use of β-blockers could exasperate their condition. Through extensive literature review on this rare condition, the most effective management was found to be therapeutic plasma exchange in order to decrease thyroid hormone levels, which have direct toxic effect on the heart. Furthermore, the use of ECMO and Impella is advised to reduce pressure on the heart and ensure the patient’s organs are well oxygenated and perfused while the left ventricle is recovering.

Keywords: Thyrotoxicosis, cardiogenic shock, shock, thyroid storm, ECMO, impella, therapeutic plasma exchange.

Graphical Abstract

[1]
Dahl P, Danzi S, Klein I. Thyrotoxic cardiac disease. Curr Heart Fail Rep 2008; 5(3): 170-6.
[http://dx.doi.org/10.1007/s11897-008-0026-9] [PMID: 18752767]
[2]
Nayak B, Burman K. Thyrotoxicosis and thyroid storm. Endocrinol Metab Clin North Am 2006; 35(4): 663-86.
[http://dx.doi.org/10.1016/j.ecl.2006.09.008] [PMID: 17127140]
[3]
Pubmeddev. Home - PubMed - NCBI [Internet]. [cited 2018 Dec 29]. Available from:. https://www.ncbi.nlm.nih.gov/pubmed/
[4]
Osuna PM, Udovcic M, Sharma MD. Hyperthyroidism and the Heart. Methodist DeBakey Cardiovasc J 2017; 13(2): 60-3.
[http://dx.doi.org/10.14797/mdcj-13-2-60] [PMID: 28740583]
[5]
Kim S, Seol S-H, Kim Y-S, Kim D-K, Kim K-H, Kim D-I. Thyrotoxicosis induced cardiogenic shock rescued by extracorporeal membrane oxygenation. J Geriatr Cardiol 2018; 15(2): 203-4.
[PMID: 29662515]
[6]
Ngo SYA, Chew HC. When the storm passes unnoticed--a case series of thyroid storm. Resuscitation 2007; 73(3): 485-90.
[http://dx.doi.org/10.1016/j.resuscitation.2006.10.003] [PMID: 17291668]
[7]
Riaz K, Forker AD, Isley WL, Hamburg MS, McCullough PA. Hyperthyroidism: a “curable” cause of congestive heart failure--three case reports and a review of the literature. Congest Heart Fail 2003; 9(1): 40-6.
[http://dx.doi.org/10.1111/j.1527-5299.2003.01124.x] [PMID: 12556677]
[8]
Eyadiel L, Amjad A, Pisani B, Miller P, Jain R. Use of therapeutic plasma exchange and ECMO support with impella for LV vent as treatment for cardiogenic shock in acute thyrotoxicosis/thyroid storm. J Cardiac Failure 2018; 24(8)(Supplement): S84-5.
[9]
Abubakar H, Singh V, Arora A, Alsunaid S. Propranolol-induced circulatory collapse in a patient with thyroid crisis and underlying thyrocardiac disease: A word of caution. J Investig Med High Impact Case Rep 2017; 5(4)2324709617747903
[http://dx.doi.org/10.1177/2324709617747903] [PMID: 29318163]
[10]
Ngo AS-Y, Lung Tan DC. Thyrotoxic heart disease. Resuscitation 2006; 70(2): 287-90.
[http://dx.doi.org/10.1016/j.resuscitation.2006.01.009] [PMID: 16806643]
[11]
Ikram H. Haemodynamic effects of beta-adrenergic blockade in hyperthyroid patients with and without heart failure. Br Med J 1977; 1(6075): 1505-7.
[http://dx.doi.org/10.1136/bmj.1.6075.1505] [PMID: 871633]
[12]
Barbier GH, Shettigar UR, Appunn DO. Clinical rationale for the use of an ultra-short acting beta-blocker: Esmolol. Int J Clin Pharmacol Ther 1995; 33(4): 212-8.
[PMID: 7620691]
[13]
Isley WL, Dahl S, Gibbs H. Use of esmolol in managing a thyrotoxic patient needing emergency surgery. Am J Med 1990; 89(1): 122-3.
[http://dx.doi.org/10.1016/0002-9343(90)90114-S] [PMID: 1973332]
[14]
Choudhury RP, MacDermot J. Heart failure in thyrotoxicosis, an approach to management. Br J Clin Pharmacol 1998; 46(5): 421-4.
[http://dx.doi.org/10.1046/j.1365-2125.1998.00804.x] [PMID: 9833593]
[15]
Mohananey D, Smilowitz N, Villablanca PA, et al. Trends in the incidence and in-hospital outcomes of cardiogenic shock complicating thyroid storm. Am J Med Sci 2017; 354(2): 159-64.
[http://dx.doi.org/10.1016/j.amjms.2017.04.017] [PMID: 28864374]
[16]
Biondi B. Mechanisms in endocrinology: Heart failure and thyroid dysfunction. Eur J Endocrinol 2012; 167(5): 609-18.
[http://dx.doi.org/10.1530/EJE-12-0627] [PMID: 22956554]
[17]
Tomisti L, Materazzi G, Bartalena L, et al. Total thyroidectomy in patients with amiodarone-induced thyrotoxicosis and severe left ventricular systolic dysfunction. J Clin Endocrinol Metab 2012; 97(10): 3515-21.
[http://dx.doi.org/10.1210/jc.2012-1797] [PMID: 22865896]
[18]
Herrmann J, Hilger P, Rusche HJ, Krüskemper HL. Plasmapheresis in the treatment of thyrotoxic crisis (author’s transl). Dtsch Med Wochenschr 1974; 99(17): 888-92.
[http://dx.doi.org/10.1055/s-0028-1107858] [PMID: 4209432]
[19]
Simsir IY, Ozdemir M, Duman S, Erdogan M, Donmez A, Ozgen AG. Therapeutic plasmapheresis in thyrotoxic patients. Endocrine 2018; 62(1): 144-8.
[http://dx.doi.org/10.1007/s12020-018-1661-x] [PMID: 29968224]
[20]
Wyble AJ, Moore SC, Yates SG. Weathering the storm: A case of thyroid storm refractory to conventional treatment benefiting from therapeutic plasma exchange. J Clin Apher 2018; 33(6): 678-81.
[http://dx.doi.org/10.1002/jca.21658] [PMID: 30321468]
[21]
Subahi A, Ibrahim W, Abugroun A. Diltiazem-associated cardiogenic shock in thyrotoxic crisis. Am J Ther 2018; 25(6): e666-9.
[http://dx.doi.org/10.1097/MJT.0000000000000739] [PMID: 29521654]
[22]
Ezer A, Caliskan K, Parlakgumus A, Belli S, Kozanoglu I, Yildirim S. Preoperative therapeutic plasma exchange in patients with thyrotoxicosis. J Clin Apher 2009; 24(3): 111-4.
[http://dx.doi.org/10.1002/jca.20200] [PMID: 19484727]
[23]
Allencherril J, Birnbaum I. Heart failure in thyrotoxic cardiomopathy: Extracorporeal membrane oxygenation treatment for graves’ disease. J Extra Corpor Technol 2015; 47(4): 231-2.
[PMID: 26834286]
[24]
Chao A, Wang C-H, You H-C, et al. Highlighting Indication of extracorporeal membrane oxygenation in endocrine emergencies. Sci Rep 2015; 5: 13361.
[http://dx.doi.org/10.1038/srep13361] [PMID: 26299943]
[25]
Chen Y-S, Chao A, Yu H-Y, et al. Analysis and results of prolonged resuscitation in cardiac arrest patients rescued by extracorporeal membrane oxygenation. J Am Coll Cardiol 2003; 41(2): 197-203.
[http://dx.doi.org/10.1016/S0735-1097(02)02716-X] [PMID: 12535808]
[26]
Litwiński P, Dębski A, Tyczyński P, et al. Rescue extracorporeal membrane oxygenation for refractory cardiogenic shock. Postepy Kardiol Interwencyjnej 2015; 11(4): 327-9.
[http://dx.doi.org/10.5114/pwki.2015.55605] [PMID: 26677384]
[27]
Chen Y-S, Lin J-W, Yu H-Y, et al. Cardiopulmonary resuscitation with assisted extracorporeal life-support vs. conventional cardiopulmonary resuscitation in adults with in-hospital cardiac arrest: An observational study and propensity analysis. Lancet 2008; 372(9638): 554-61.
[http://dx.doi.org/10.1016/S0140-6736(08)60958-7] [PMID: 18603291]
[28]
Ko W-J, Lin C-Y, Chen RJ, Wang S-S, Lin F-Y, Chen Y-S. Extracorporeal membrane oxygenation support for adult postcardiotomy cardiogenic shock. Ann Thorac Surg 2002; 73(2): 538-45.
[http://dx.doi.org/10.1016/S0003-4975(01)03330-6] [PMID: 11845871]
[29]
Peek GJ, Mugford M, Tiruvoipati R, et al. CESAR trial collaboration. Efficacy and economic assessment of conventional ventilatory support vs. extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): A multicentre randomised controlled trial. Lancet 2009; 374(9698): 1351-63.
[http://dx.doi.org/10.1016/S0140-6736(09)61069-2] [PMID: 19762075]
[30]
Schrage B, Burkhoff D, Rübsamen N, et al. Unloading of the left ventricle during venoarterial extracorporeal membrane oxygenation therapy in cardiogenic shock. JACC Heart Fail 2018; 6(12): 1035-43.
[http://dx.doi.org/10.1016/j.jchf.2018.09.009] [PMID: 30497643]
[31]
White A, Bozso SJ, Moon MC. Thyrotoxicosis induced cardiomyopathy requiring support with extracorporeal membrane oxygenation. J Crit Care 2018; 45: 140-3.
[http://dx.doi.org/10.1016/j.jcrc.2018.01.026] [PMID: 29475150]
[32]
Colombier S, Quessard A, Mastroianni C, et al. Benefits of impella and peripheral veno-arterial extra corporeal life support alliance. ASAIO J 2018.
[PMID: 30575629]
[33]
Kiriyama H, Amiya E, Hatano M, et al. Rapid Improvement of thyroid storm-related hemodynamic collapse by aggressive anti-thyroid therapy including steroid pulse: A case report. Medicine (Baltimore) 2017; 96(22)e7053
[http://dx.doi.org/10.1097/MD.0000000000007053] [PMID: 28562568]
[34]
Koball S, Hickstein H, Gloger M, et al. Treatment of thyrotoxic crisis with plasmapheresis and single pass albumin dialysis: A case report. Artif Organs 2010; 34(2): E55-8.
[http://dx.doi.org/10.1111/j.1525-1594.2009.00924.x] [PMID: 20420590]
[35]
Hsu L-M, Ko W-J, Wang C-H. Extracorporeal membrane oxygenation rescues thyrotoxicosis-related circulatory collapse. Thyroid 2011; 21(4): 439-41.
[http://dx.doi.org/10.1089/thy.2010.0230] [PMID: 21385078]
[36]
Palkar AV, Shrivastava MS, Moulick ND. An unusual cause of flash pulmonary oedemaBMJ Case Rep 2012 2012, 2012..
[http://dx.doi.org/10.1136/bcr.03.2012.6087] [PMID: 22707683]